(Q36639862)

15 August 2017

1 reference

title

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor (English)

1 reference

15 August 2017

0 references

opportunistic infection

1 reference

1

Kevin L Winthrop

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

602-610

1 reference

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

Extrapulmonary tuberculosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Infections associated with tumor necrosis factor-alpha antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tuberculosis associated with therapy against tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor: biology and therapeutic inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Advances in the therapy of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Treatment of sarcoidosis with infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Reactivation of latent granulomatous infections by infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Global incidence of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0336

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0336

1 reference

15 August 2017

1 reference